

LIMPII/SR-B2 Protein, Human, Recombinant (hFc)

General Information

Synonyms:	LIMP-2;AMRF;LGP85;CD36L2;LIMPII;HLGP85;SR-BII;scavenger receptor class B, member 2; EPM4
Protein Construction:	A DNA sequence encoding the human SIGLEC15 (NP_005497.1) (Arg27-Thr432) was expressed with the Fc region of human IgG1 at the C-terminus. Predicted N terminal: Arg27
Species:	Human
Expression Host:	HEK293 Cells
Accession:	Q14108
Molecular Weight:	73.26 kDa (predicted)

QC Testing

Biological Activity:	Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	> 95 % as determined by SDS-PAGE.
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Lysosomal Integral Membrane Protein II (LIMPII), also known as SCARB2, LPG85, and CD36L2, is a type II multi-pass membrane glycoprotein that is located primarily in limiting membranes of lysosomes and endosomes on all tissues and cell types so far examined. This protein may participate in membrane transportation and the reorganization of endosomal/lysosomal compartment. LIMPII is identified as a receptor for EV71 (human

enterovirus species A, Enterovirus 71) and CVA16 (coxsackievirus A16) which are most frequently associated with hand, foot and mouth disease (HFMD). Expression of human LIMPII enables normally unsusceptible cell lines to support the viruses' propagation and develop cytopathic effects. In addition, LIMPII also has been shown to bind thrombospondin-1, and may contribute to the pro-adhesive changes of activated platelets during coagulation, and inflammation. Deficiency of the protein in mice impairs cell membrane transport processes and causes pelvic junction obstruction, deafness, and peripheral neuropathy.

Reference

- Crombie, R. et al., 1998, J. Biol. Chem. 273: 4855-4863.
Febbraio, M. et al., 2001, J. Clin. Invest. 108: 785-791.
Kuronita, T. et al., 2002, J. Cell Sci. 115: 4117-4131.
Gamp, A.C. et al., 2003, Human Molecular Genetics. 12: 631-646.
Eskelinen, E.L. et al., 2003, Trends in Cell Biology. 13: 137-145.
Mulcahy, J.V. et al., 2004, Biochem. J. 377 (Pt 3): 741-747.
Yamayoshi, S. et al., 2009, Nat Med. 15 (7): 798-801.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481